H.C. Wainwright raised the firm’s price target on Zymeworks (ZYME) to $32 from $26 and keeps a Buy rating on the shares. Ziihera plus chemotherapy and Ziihera plus Tevimbra and chemotherapy demonstrated “highly statistically significant” and clinically meaningful improvements in progression-free survival compared to the control arm, trastuzumab plus chemotherapy, the analyst tells investors in a research note. Given the data, the firm upped its probability of approval for Ziihera in first-line HER2+ gastroesophageal adenocarcinoma to 90% from 60%.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Zymeworks announces new $125M share repurchase plan
- Zymeworks announces strategic initiative to optimize Ziihera cash flows
- Zymeworks appoints Scott Platshon as acting chief investment officer
- Zymeworks Stock (ZYME) Soars on Positive Results for Cancer Drug Ziihera, Top Analysts Boost Price Targets
- Zymeworks Stock Upgraded to ‘Buy’ on Promising Phase 3 Trial Results and Financial Prospects